Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
You are about to leave the Ultragenyx website.
Do you want to continue?
This site uses cookies to provide you with a more responsive and personalized service. By clicking "Accept" below, you agree to the use of cookies on this site. Please read our Cookie Policy and Privacy Policy for more information on the use of cookies on this website.